Reliable antimicrobial resistance surveillance depends on more than laboratory instruments and trained personnel. Every reported result also relies on the timely availability of collection devices, transport materials, culture media, identification reagents, susceptibility-testing products, quality-control strains, and protective items. Effective diagnostic consumables planning connects these materials to the surveillance protocol, expected workload, testing platform, laboratory capacity, and reporting calendar. This connection helps laboratories protect data continuity while avoiding unnecessary expiry, uncontrolled substitutions, and fragmented purchasing decisions.
Planning should begin with the surveillance design and move backward through each analytical step. The target pathogens, specimen types, participating sites, approved methods, testing frequency, and referral arrangements determine what must be stocked and where. The WHO GLASS framework emphasizes standardized collection, analysis, interpretation, and sharing of AMR data, so consumable availability must support consistent methods across the network. A practical plan therefore combines technical specifications, demand forecasts, supplier controls, storage rules, traceability, and contingency measures in one reviewable system.
Surveillance data can become incomplete or incomparable when laboratories run out of a single high-dependency item. A shortage of blood-culture bottles, identification reagents, antibiotic disks, inoculum-standardization materials, or quality-control products may interrupt the testing pathway even when all major equipment remains operational. Careful planning keeps AMR surveillance consumables synchronized with sample intake and protects the laboratory from gaps that could reduce the representativeness, timeliness, or reliability of reported resistance patterns.
Planning also gives procurement and laboratory teams a shared operational view. Instead of reacting to low stock after testing has already been affected, they can review consumption, expiry exposure, open orders, supplier lead times, and anticipated program changes together. This is particularly important in multisite networks, where a central warehouse may appear adequately stocked while individual sentinel laboratories face local shortages. A coordinated plan supports consistent test performance, predictable budgets, controlled inventory movement, and documented decisions when demand or methods change.
Testing requirements should be translated from the approved surveillance protocol into a detailed workload model. Laboratories need to identify included infection types, specimen sources, priority organisms, antimicrobial panels, testing methods, confirmation pathways, quality-control frequency, and reporting intervals. The current WHO GLASS-AMR manual provides a useful methodological reference, but national guidelines, reference-laboratory instructions, and the laboratory’s validated procedures must determine the final bill of materials. Each method should be mapped from specimen receipt through result authorization.
The requirements register should separate routine testing from referral, confirmation, external quality assessment, training, method verification, and outbreak-related work. It should also record the analyzer model or manual technique, pack size, unit of use, storage condition, minimum remaining shelf life at receipt, and acceptable alternative for every item. This level of detail prevents procurement teams from treating technically different products as interchangeable. It also makes changes visible when a new site joins, an antibiotic panel expands, or the surveillance program adds another specimen category.
Each target pathogen and specimen type creates a distinct chain of material requirements. Blood, urine, stool, genital, respiratory, and wound specimens may require different collection containers, transport conditions, primary media, selective media, incubation workflows, identification tests, and susceptibility panels. Laboratories should build a method-to-item matrix that links every reportable organism to its approved workflow. This reveals shared products, pathogen-specific items, and single points of failure while preventing irrelevant stock from being included merely because it is common in routine microbiology.
Site-level forecasts should use recent eligible specimen volumes, positivity rates, isolate yields, rejection rates, repeat-testing frequency, and expected program growth. A central laboratory should not apply one consumption factor uniformly when sentinel sites serve different populations or use different referral pathways. Monthly forecasts should therefore show baseline, expected, and surge scenarios for each location. New sites may require a ramp-up profile based on capacity and training milestones, while established sites can use rolling consumption adjusted for seasonality, service interruptions, and changes in clinical sampling practices.
The required inventory should cover the entire pre-analytical, analytical, and post-analytical workflow rather than focusing only on susceptibility testing. Core categories generally include specimen-collection devices, leak-resistant packaging, transport media, culture media, stains, identification reagents, susceptibility-testing materials, quality-control products, sterile disposables, cleaning and disinfection items, labels, and biosafety supplies. The exact list of antimicrobial resistance laboratory supplies must reflect the program’s organisms, specimens, validated methods, equipment, and national reporting requirements.
Laboratories should distinguish between universal products, method-specific products, and items that are critical but rarely used. Universal items may be forecast from total workload, whereas method-specific products require forecasts tied to eligible isolates or instrument runs. Rare confirmation materials need a different policy because low use can increase expiry risk even though immediate availability remains important. A structured item master should record technical specifications, catalog references, compatible equipment, pack configuration, storage range, shelf life, hazard status, and approved substitutions for every controlled product.
Collection and transport materials protect specimen integrity before testing begins. Depending on the surveillance scope, laboratories may need blood-culture bottles, sterile urine containers, swabs, stool containers, transport media, specimen bags, absorbent material, tamper-evident seals, labels, and compliant secondary packaging. Forecasts should include collection-site wastage, rejected specimens, damaged packaging, and transport frequency. Products must match the specimen, collection method, transport time, and laboratory procedure; otherwise, poor recovery or contamination can compromise both patient-level results and the surveillance dataset.
Culture and identification workflows may require dehydrated or prepared media, agar plates, broths, biochemical reagents, stains, immersion oil, sterile loops, pipette tips, tubes, cuvettes, identification cards, or mass-spectrometry target materials. These microbiology laboratory consumables should be mapped to the likely number of primary cultures, subcultures, isolates, controls, and repeat tests rather than ordered from specimen counts alone. Media sterility, growth performance, lot consistency, and storage conditions should be verified, while short-dated products should be ordered in quantities that can be consumed before expiry.
Susceptibility testing may use antibiotic disks, gradient strips, broth microdilution panels, automated cards, microplates, inoculation devices, turbidity standards, saline, cation-adjusted media, agar, and measurement tools. All AST consumables must match the laboratory’s validated method and the interpretive standard used for reporting. Procurement specifications should identify content, potency, panel configuration, compatible organism groups, storage conditions, and remaining shelf life. Forecasts must also include quality-control runs, repeat tests, confirmatory work, verification of new lots, and additional testing triggered by unusual resistance results.
Quality control requires reference strains, preservation materials, purity-check media, control reagents, proficiency-testing materials, and documentation labels or records appropriate to the local system. Biosafety needs may include gloves, gowns, eye protection, respirator products where risk-assessed, disinfectants, spill materials, sharps containers, autoclavable waste bags, and surface-monitoring supplies. These items should not be forecast as a simple percentage of patient tests when their use follows scheduled controls, work shifts, staff numbers, incidents, or decontamination cycles. Minimum stock levels should reflect their role in safely releasing valid results.
A defensible forecast begins with a clear unit of use. The laboratory should determine how many units of each product are consumed per specimen, positive culture, isolate, susceptibility test, instrument run, quality-control event, or workday. Historical issues data can then be adjusted for current testing demand, program expansion, seasonality, pack size, open-vial stability, and expected wastage. Forecasts should be calculated at item and site level before being consolidated, because network totals can hide important differences in method, throughput, and stock position.
Forecasts should cover a defined planning horizon that includes procurement lead time, review time, and the intended supply interval. Teams can compare a consumption-based forecast with a service-based forecast derived from expected tests, investigating large differences before approval. The final quantity should account for usable stock on hand, confirmed inbound orders, quarantined inventory, stock reserved for other programs, and products likely to expire. Assumptions should be documented and reviewed regularly so the model changes when testing activity, methods, or supplier performance changes.
Routine demand can be calculated by multiplying expected activity by the validated consumption factor for each item, then adding scheduled quality-control and verification use. Wastage should be modeled separately rather than hidden inside an arbitrary uplift. Relevant causes include open-pack expiry, breakage, contamination, failed runs, rejected specimens, training, temperature excursions, and minimum pack size. Comparing forecast use with actual issues and discarded quantities helps laboratories refine each factor. Items with high wastage need operational review, smaller packs, more frequent delivery, or redistribution before simply increasing future orders.
Safety stock should reflect variability in both demand and replenishment rather than one standard percentage for every product. Criticality, supplier reliability, transport route, customs exposure, shelf life, substitution options, and the consequences of a stockout all matter. A practical reorder point equals expected use during total replenishment lead time plus the approved safety stock. Laboratories should define an alert level, reorder level, and emergency level for critical products, then recalculate them when consumption or lead time changes. Excess buffers should be avoided when expiry risk is greater than supply risk.
Product selection should be driven by method suitability and evidence, not only by unit price or catalog description. The laboratory must confirm that a consumable supports the approved procedure, target organism, specimen type, equipment, quality-control acceptance criteria, and interpretive approach. The assessment should also consider sterility or performance claims, manufacturing controls, lot documentation, packaging configuration, transport conditions, and local regulatory requirements. Products that appear equivalent commercially may differ in formulation, concentration, dimensions, panel content, software recognition, or stability after opening.
Selection decisions should involve laboratory scientists, quality personnel, procurement staff, warehouse teams, and technical users of the relevant equipment. A standardized specification and evaluation record allows bids to be compared against mandatory and desirable criteria. Any proposed alternative should pass a documented technical review before purchase, and verification requirements should be defined in advance. Total cost should include controls, repeat testing, waste, specialized storage, calibration implications, freight, and disposal—not simply the price of the primary pack.
Compatibility checks should reference the current standard operating procedure, instrument instructions, validated media or reagent requirements, and laboratory information-system configuration where relevant. Automated cards, panels, tubes, cuvettes, or proprietary reagents may need specific instrument versions, software libraries, incubation conditions, or accessories. Manual products also require technical consistency in dimensions, concentration, potency, and endpoint reading. The laboratory should document whether a product is fully compatible, conditionally acceptable after verification, or prohibited. Catalog-number changes should trigger review rather than being treated automatically as administrative updates.
Remaining shelf life at delivery should be long enough to cover receipt, quarantine, distribution, and expected consumption without forcing premature use. Procurement documents should state required storage ranges, protection from light or moisture, shipping controls, acceptable pack sizes, and minimum expiry at receipt. Open-container or on-board stability can be more restrictive than the printed expiry date and must be included in demand calculations. Packaging should protect sterility and performance throughout distribution, while unit sizes should suit site throughput so smaller laboratories do not discard partially used packs repeatedly.
Required documentation may include manufacturer details, product specifications, certificates of analysis or conformity, lot and expiry information, safety data sheets, transport records, and evidence of applicable regulatory status. The exact document set depends on product classification, national rules, institutional policy, and the intended market. Quality teams should confirm that documents correspond to the supplied catalog and lot, remain current, and support traceability. Marketing claims alone are insufficient. Records should be retained in a form that allows the laboratory to reconstruct selection, receipt, release, distribution, and use during audits or investigations.
Supplier qualification should establish whether the vendor can consistently deliver the specified product under controlled conditions. The review may cover authorization to supply, manufacturer relationships, quality systems, recall procedures, complaint handling, storage facilities, temperature management, lead-time history, continuity arrangements, and document accuracy. For AMR surveillance procurement, critical or single-source items deserve more intensive evaluation than common low-risk disposables. Laboratories should also identify which products are supplied directly, through distributors, or via intermediaries, because accountability and traceability can differ across those routes.
Incoming verification then confirms that each delivery matches the purchase order and remains suitable for laboratory release. Staff should inspect product identity, catalog number, quantity, lot, expiry, packaging integrity, temperature evidence where required, and accompanying documents. Discrepancies should place stock in quarantine until resolved. Technical acceptance testing may be necessary for new products, changed formulations, new lots, or high-impact materials. Receipt and release records should link the supplier shipment to internal stock locations and, where feasible, to subsequent laboratory use.
A supplier scorecard should combine technical compliance with service performance. Useful criteria include complete documentation, on-time and in-full delivery, temperature-control performance, response to complaints, recall communication, backorder frequency, and willingness to provide advance notice of product changes. The evaluation should be based on defined evidence and reviewed at an interval proportionate to risk. Approved status should be product- or category-specific when necessary; a supplier that performs well for general disposables may not automatically be suitable for temperature-sensitive reagents or specialized susceptibility panels.
Lot verification confirms that a newly received batch performs within established acceptance criteria before routine use when such testing is required. The protocol should specify which products need verification, the control organisms or materials, test conditions, expected results, responsible personnel, and release authority. Laboratories should retain samples or records according to policy and investigate failures before changing criteria or repeating tests. Results must be linked to the exact lot and expiry. If multiple sites use the same batch, a coordinated central verification may reduce duplication only when governance permits and distribution traceability remains intact.
Storage conditions should preserve product performance from receipt through final use. Warehouses and laboratories need mapped temperature zones, monitored refrigerators or freezers where applicable, humidity and light controls where specified, clean shelving, segregation of quarantined or recalled stock, and backup arrangements for power or equipment failure. Inventory records should show location, lot, expiry, status, and available quantity. Staff should avoid storing products in uncontrolled spaces merely because the main warehouse is full, since short excursions or poor segregation can invalidate otherwise acceptable stock.
Distribution should follow documented requisitions and allocate stock according to consumption, criticality, remaining inventory, and expiry. Central stores should not split packs in ways that damage labeling or storage integrity. Sites need clear receiving responsibilities and should confirm quantities, lots, condition, and temperature evidence on arrival. Regular reconciliation between physical stock and electronic records helps detect errors early. Redistribution can reduce expiry and shortages, but products should move only when transport conditions, chain of custody, remaining shelf life, and receiving-site compatibility are confirmed.
Temperature-sensitive products require validated storage ranges, calibrated monitoring devices, documented alarm response, and an assessment process for excursions. First-expiry, first-out management should guide routine picking, provided that recalled, quarantined, or nonconforming stock is excluded. Batch traceability should connect receipt, internal movement, issue, and laboratory use wherever operationally feasible. This makes it possible to identify affected sites quickly when a manufacturer issues a notice or when performance concerns emerge. Periodic stock checks should compare physical lots and expiry dates with the inventory system, not only total quantities.
Allocation should balance equitable access with actual workload and risk. Central stores can use site-level consumption, current stock, days of cover, pending deliveries, storage capacity, and critical testing commitments to decide quantities. Sentinel laboratories should receive enough stock to operate through the next planned distribution plus an approved buffer, without holding excess short-dated inventory. Programs also need rules for emergency transfers between sites. A network dashboard that displays comparable stock indicators can reveal imbalances early and support redistribution before one laboratory stops testing while another holds surplus material.
Stockout prevention requires early warning, disciplined ordering, and a response pathway that is agreed before inventory becomes critical. Laboratories should review consumption, days of cover, pending purchase orders, supplier confirmations, and expiry exposure for high-priority items at a defined frequency. Alerts must reach both technical and procurement owners, with named responsibility for follow-up. Long-lead, single-source, temperature-sensitive, or method-locked products should receive closer monitoring because a delay may not be solved through local purchasing or rapid substitution.
Prevention also depends on reducing avoidable variability. Standardized item codes, approved product lists, realistic order calendars, consolidated demand, framework agreements, and clear release procedures can shorten administrative delays. Programs should maintain a continuity register that records alternative suppliers, technically acceptable substitutes, emergency transfer options, and the testing impact of each shortage scenario. When a risk is identified, the response may include expediting, phased delivery, stock redistribution, workload referral, or controlled prioritization; every action should protect method consistency and data integrity.
Total lead time includes internal approval, tender or quotation activity, supplier processing, manufacturing or backorder time, transport, customs clearance, receipt, quarantine, verification, and distribution to the testing site. Measuring only shipment time creates a misleading reorder point. Teams should compare planned and actual lead times by item and supplier, then update forecasts when delays recur. An emergency replenishment procedure should define authorization, funding, approved sourcing routes, transport controls, receiving checks, and communication. Emergency purchase speed should never remove essential technical review or product traceability.
Substitution should be treated as a controlled technical change, not a procurement shortcut. The laboratory must assess method compatibility, performance evidence, quality-control implications, equipment settings, interpretive consequences, staff training, and validation or verification needs before use. A preapproved substitution matrix can accelerate decisions, but it should state the exact product, conditions, and approving authority. If no suitable substitute exists, the continuity plan may redirect specimens, modify nonessential schedules, or prioritize critical surveillance functions. Any temporary change should be documented so resulting data remain interpretable.
Inventory indicators should help teams act before testing is affected. A balanced dashboard needs measures of availability, consumption, supplier reliability, expiry, data accuracy, and service continuity rather than a single stock-on-hand figure. Indicators should be calculated consistently at central and site levels, with thresholds that reflect item criticality. Reviewing trends is more useful than looking at an isolated month, because a gradually falling delivery rate or rising adjustment value can reveal a developing control problem even while stock remains available.
Each KPI should have an owner, data source, review frequency, threshold, and required response. High-priority items may need weekly monitoring, while stable low-risk categories can be reviewed monthly. Teams should investigate exceptions by product and site, record corrective action, and assess whether the indicator improved. Dashboard totals should never conceal critical individual items. For example, a high overall service level does not compensate for repeated shortages of a product that is essential to release valid susceptibility results.
KPI | Practical Measurement | Management Use |
Stockout rate | Critical items unavailable during the period | Identifies direct threats to testing continuity |
Days of cover | Usable stock divided by average daily use | Supports reorder and redistribution decisions |
Expiry and wastage rate | Discarded units divided by units available | Highlights overstocking and pack-size problems |
On-time, in-full delivery | Complete orders received by the promised date | Tracks supplier reliability |
Inventory accuracy | Physical count compared with recorded balance | Reveals transaction and control errors |
Emergency order rate | Urgent orders divided by total orders | Shows weaknesses in forecasting or lead-time control |
Corena can consolidate program-specific laboratory supplies against an approved item list, technical specification, required quantity, delivery schedule, and destination. The sourcing workflow can cover collection products, culture materials, diagnostic items, laboratory disposables, PPE, and compatible supporting products while keeping manufacturer documentation, lot details, expiry expectations, and packaging requirements visible. This approach is especially useful when a surveillance program needs multiple product categories from different manufacturers but requires coordinated documentation and delivery.
For cross-border programs, Corena’s medical supplies procurement and medical product export capabilities can align sourcing, quality checks, export documentation, shipment planning, and temperature-controlled logistics where applicable. Buyers should provide the validated method, equipment model, catalog reference or performance specification, destination requirements, and minimum remaining shelf life before quotation. Clear technical inputs allow the proposed supply plan to be reviewed for compatibility, traceability, delivery risk, and continuity before purchase approval.
The following questions address common operational decisions about buffer stock, temperature-sensitive products, and forecast review. Exact requirements should always follow the surveillance protocol, validated laboratory methods, manufacturer instructions, national regulations, quality procedures, and the risk profile of each item rather than a universal purchasing rule.
There is no single percentage suitable for every laboratory or product. Safety stock should cover plausible demand and lead-time variation according to item criticality, supplier reliability, shelf life, substitution options, transport risk, and consequences of interruption. Laboratories can calculate the buffer separately for each critical item, review it against days of cover, and adjust it when workload or replenishment performance changes. Short-dated products may require smaller buffers supported by more frequent deliveries or network redistribution.
Cold-chain requirements depend on the manufacturer’s labeled conditions and may apply to selected reagents, antibiotic disks, susceptibility panels, quality-control materials, culture products, or molecular diagnostic components. Some products require refrigeration, others freezing, and some controlled room temperature; assumptions based on product category are unsafe. Teams should verify storage and shipping ranges, open-pack stability, light or moisture protection, monitoring requirements, excursion procedures, and last-mile conditions before procurement, receipt, distribution, and use.
Programs should review critical-item forecasts frequently enough to act within the replenishment lead time, often monthly and more frequently for unstable or high-risk products. A full forecast can be refreshed quarterly or when testing scope, site participation, methods, workload, supplier performance, or funding changes materially. Routine reviews should compare forecast demand with actual consumption, wastage, stock on hand, open orders, and expiry exposure. Any significant variance should update both future quantities and the assumptions behind them.
Corena is a global provider of Healthcare Solutions, offering pharmaceuticals, medical devices, dental, veterinary, and laboratory products. Since 2009, we have supported emergency response, rare disease treatments, and clinical trial supplies with reliable and customer-focused services.